HCA
CYTK icon

Harbor Capital Advisors’s Cytokinetics CYTK Stock Holding History

Harbor Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53,113
Closed -$2.13M – 1390
2025
Q1 		$2.13M Buy
53,113
+7,983
+18% +$367K 0.1% 274
2024
Q4 		$2.12M Buy
45,130
+2,604
+6% +$135K 0.09% 267
2024
Q3 		$2.25M Buy
42,526
+24,712
+139% +$1.38M 0.1% 282
2024
Q2 		$965K Buy
17,814
+14,270
+403% +$861K 0.07% 365
2024
Q1 		$248K Buy
+3,544
New +$274K 0.03% 558
2023
Q3 		– Sell
-722
Closed -$23.6K – 497
2023
Q2 		$23.6K Buy
+722
New +$26.7K ﹤0.01% 570

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Harbor Capital Advisors's CYTK Position: Q2 2025 in Review

Harbor Capital Advisors sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 53,113 shares — an estimated $2.13M sold.

Harbor Capital Advisors first reported a position in CYTK in Q2 2023 and held it in 6 quarters. The position peaked at $2.25M in Q3 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Harbor Capital Advisors reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 53,113 Cytokinetics shares in Q2 2025, an estimated $2.13M.
  • Harbor Capital Advisors first reported a position in Cytokinetics in Q2 2023 and held it in 6 quarters.
  • Harbor Capital Advisors's Cytokinetics position peaked at $2.25M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Harbor Capital Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.